asthma
NICE consults on asthma drug reducing procedure
July 26, 2011Sales and Marketing NICE, asthma
NICE has launched a consultation in the UK on a new medical procedure which, if it proves safe and effective, …
Pfizer drops early-stage asthma candidate
May 11, 2011Research and Development Pfizer, Rigel, asthma
Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals. San Francisco-based Rigel says Pfizer is …
AZ stops making Pulmicort pMDI inhaler
March 8, 2011Manufacturing and Production AZ, AstraZeneca, Pulmicort, Pulmicort pMDI, Skyepharma, asthma, asthma inhaler, budesonide
AstraZeneca has discontinued production of its Pulmicort pMDI asthma inhaler because of manufacturing issues, and looks set to exit from …
New COPD and asthma treatments jostle for market space
October 6, 2010Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma
Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …
Gene-targeting asthma drugs within a decade
September 24, 2010Research and Development asthma, genetic
Asthma treatments that target genetic variants found in people susceptible to the condition could be available within the next ten …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
MSD launches asthma training resources
August 6, 2010Medical Communications, Sales and Marketing MSD, asthma, medical education, merck sharp and dohme, nurses
A new training resource aimed at helping primary care nurses manage asthma has been launched with funding from Merck Sharp …
NICE rejects Xolair for children
June 3, 2010Sales and Marketing NICE, Xolair, asthma
The drug was first approved in Europe in November 2005 for patients aged 12 or older, and gained NICE approval …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
